BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
Go back to BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 9.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.96 | 52 Week High | $10.98 | |||
| Open | $9.96 | 52 Week Low | $1.63 | |||
| Day High | $9.96 | P/E | N/A | |||
| Day Low | $9.96 | EPS | $-0.68 | |||
| Volume | 81,021 | |||||
